Biotinylated Anti-PD-1(toripalimab biosimilar) mAb Cat. No. BME100703B



PRODUCT INFORMATION

Common Name	CHS-007;CHS007;CHS 007;CHS-7;CHS7;CHS 7;JS 001;JS001;JS-001;JS1;JS-1;JS 1;SO-001;SO 001;SO001;SO1;SO-1;SO 1;TAB-001;TAB001;TAB 001;TAB1;TAB-1;TAB 1;Tripleitriumab;Triprizumab;Tuoyi
Synonyms	PD1;PD-1;CD279;SLEB2;hPD-1;hPD-l;hSLE1
Applications	N/A
Recommended Dilutions	N/A
Formulation & Reconstitution	Lyophilized from sterile PBS, pH 7.4. Normally 5 % – 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
Host Species	N/A
lgG type	lgG4
Reactivity	Human
Target	PD-1
Uniprot ID	Q15116
Description	Biotinylated Anti-PD-1(toripalimab biosimilar) mAb
Delivery	6-8 weeks
Storage & Shipping	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
Background	Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
Usage	Research use only
Conjugate	Biotinylated
DIMA Disclaimer	All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.

Email: info@dimabio.com Website: www.dimabio.com

